{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:32:41Z","timestamp":1793151161724,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2023-00305161"],"award-info":[{"award-number":["RS-2023-00305161"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2025-24523339"],"award-info":[{"award-number":["RS-2025-24523339"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhep-reports.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JHEP Reports"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jhepr.2026.101901","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:35:09Z","timestamp":1779320109000},"page":"101901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic significance of pretreatment 18F-FDG PET\/CT in hepatocellular carcinoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"8","author":[{"given":"Ji Hye","family":"Min","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Saeid","family":"Rezaee-Zavareh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman M.","family":"Attia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Young","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Jung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Yalda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasmik","family":"Adetyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Hemadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-seok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6409-1333","authenticated-orcid":false,"given":"Bachir","family":"Taouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit G.","family":"Singal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7834-9825","authenticated-orcid":false,"given":"Ju Dong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhepr.2026.101901_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhepr.2026.101901_bib2","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101901_bib3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jhepr.2026.101901_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s00261-015-0603-9","article-title":"Prognostic significance of parameters from pretreatment (18)F-FDG PET in hepatocellular carcinoma: a meta-analysis","volume":"41","author":"Sun","year":"2016","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.jhepr.2026.101901_bib5","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhepr.2026.101901_bib6","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0168-8278(00)80248-2","article-title":"Positron emission tomography scanning in the evaluation of hepatocellular carcinoma","volume":"32","author":"Khan","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101901_bib7","doi-asserted-by":"crossref","first-page":"6268","DOI":"10.21037\/qims-22-1420","article-title":"The application of (18)F-FDG PET\/CT imaging for human hepatocellular carcinoma: a narrative review","volume":"13","author":"Yao","year":"2023","journal-title":"Quant Imaging Med Surg"},{"key":"10.1016\/j.jhepr.2026.101901_bib8","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.2967\/jnumed.123.265712","article-title":"Comparison of baseline (68)Ga-FAPI and (18)F-FDG PET\/CT for prediction of response and clinical outcome in patients with unresectable hepatocellular carcinoma treated with PD-1 inhibitor and lenvatinib","volume":"64","author":"Wu","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jhepr.2026.101901_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.4174\/astr.2018.94.4.183","article-title":"Prognosis of preoperative positron emission tomography uptake in hepatectomy patients","volume":"94","author":"Kim","year":"2018","journal-title":"Ann Surg Treat Res"},{"key":"10.1016\/j.jhepr.2026.101901_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jhepr.2026.101901_bib11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jhepr.2026.101901_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jhepr.2026.101901_bib13","doi-asserted-by":"crossref","first-page":"17132","DOI":"10.3748\/wjg.v20.i45.17132","article-title":"Evaluation of prognostic factors on recurrence after curative resections for hepatocellular carcinoma","volume":"20","author":"Han","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101901_bib14","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1111\/jgh.12611","article-title":"Positioning of 18F-fluorodeoxyglucose-positron emission tomography imaging in the management algorithm of hepatocellular carcinoma","volume":"29","author":"Kawamura","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101901_bib15","doi-asserted-by":"crossref","first-page":"10406","DOI":"10.3748\/wjg.v22.i47.10406","article-title":"Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization","volume":"22","author":"Abuodeh","year":"2016","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101901_bib16","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.ejso.2013.06.019","article-title":"A survival benefit of major hepatectomy for hepatocellular carcinoma identified by preoperative [18F] fluorodeoxyglucose positron emission tomography in patients with well-preserved hepatic function","volume":"39","author":"Ahn","year":"2013","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.jhepr.2026.101901_bib17","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00432-022-04009-x","article-title":"Impact of metabolic indices of (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography on post transplantation recurrence of hepatocellular carcinoma","volume":"149","author":"Bauschke","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jhepr.2026.101901_bib18","article-title":"18F-Fluorodeoxyglucose (FDG) and 18F-fluorocholine (FCH) positron emission tomography (PET) as early predictive factorsof overall survival in patients with advanced hepatocellular carcinoma treated WithSorafenib: a prospectivemulticentricstudy","volume":"50","author":"Besson","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jhepr.2026.101901_bib19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/lt.25956","article-title":"Incorporating tumor biology to predict hepatocellular carcinoma recurrence in patients undergoing living donor liver transplantation using expanded selection criteria","volume":"27","author":"Bhangui","year":"2021","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2026.101901_bib20","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.18632\/oncotarget.23423","article-title":"Signature of survival: a (18)F-FDG PET based whole-liver radiomic analysis predicts survival after (90)Y-TARE for hepatocellular carcinoma","volume":"9","author":"Blanc-Durand","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhepr.2026.101901_bib21","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.21037\/atm-20-1583","article-title":"Clinical impact of anatomical resection on long-term outcomes after hepatectomy for primary solitary hepatocellular carcinoma with or without preoperative positron emission tomography positivity","volume":"8","author":"Cho","year":"2020","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jhepr.2026.101901_bib22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.5152\/tjg.2015.0152","article-title":"18F-FDG PET CT as a prognostic factor in hepatocellular carcinoma","volume":"26","author":"Cho","year":"2015","journal-title":"Turk J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101901_bib23","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3892\/ol.2020.11681","article-title":"Predicting tumor recurrence using metabolic indices of (18)F-FDG PET\/CT prior to orthotopic liver transplantationfor hepatocellular carcinoma","volume":"20","author":"Ding","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.jhepr.2026.101901_bib24","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3892\/etm.2010.126","article-title":"FDG positron emission tomography\/computed tomography findings for the prediction of early recurrence of hepatocellular carcinoma after surgical resection","volume":"1","author":"Hiraoka","year":"2010","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jhepr.2026.101901_bib25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/RLU.0000000000001449","article-title":"Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET\/CT in patients with very early and early hepatocellular carcinoma","volume":"42","author":"Hwang","year":"2017","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.jhepr.2026.101901_bib26","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1007\/s00268-018-4468-2","article-title":"Prognostic prediction models for resection of large hepatocellular carcinoma: a Korean multicenter study","volume":"42","author":"Hwang","year":"2018","journal-title":"World J Surg"},{"key":"10.1016\/j.jhepr.2026.101901_bib27","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1007\/s00259-016-3348-y","article-title":"Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study","volume":"43","author":"Hyun","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jhepr.2026.101901_bib28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s40644-020-00356-5","article-title":"Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with small hepatocellular carcinoma treated by radiofrequency ablation","volume":"20","author":"Ida","year":"2020","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.jhepr.2026.101901_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1044902","article-title":"Prognostic values of ALDOB expression and (18)F-FDG PET\/CT in hepatocellular carcinoma","volume":"12","author":"Jia","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jhepr.2026.101901_bib30","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/MNM.0000000000001478","article-title":"The value of preoperative 18F-FDG PET metabolic and volumetric parameters in predicting microvascular invasion and postoperative recurrence of hepatocellular carcinoma","volume":"43","author":"Jiang","year":"2022","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.jhepr.2026.101901_bib31","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/lt.25743","article-title":"Addition of [(18) F]fluorodeoxyglucose positron emission tomography with computed tomography to cross-sectional imaging improves staging and alters management in hepatocellular carcinoma","volume":"26","author":"John","year":"2020","journal-title":"Liver Transpl"},{"key":"10.1016\/j.jhepr.2026.101901_bib32","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s00259-017-3653-0","article-title":"(18)F-FDG PET\/CT predicts survival after (90)Y transarterial radioembolization in unresectable hepatocellular carcinoma","volume":"44","author":"Jreige","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jhepr.2026.101901_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2024.111551","article-title":"Combined Hounsfield units of hepatocellular carcinoma on computed tomography and PET as a noninvasive predictor of early recurrence after living donor liver transplantation: time-to-recurrence survival analysis","volume":"177","author":"Kan","year":"2024","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.jhepr.2026.101901_bib34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.3390\/jcm11020354","article-title":"Predicting the recurrence of hepatocellular carcinoma after primary living donor liver transplantation using metabolic parameters obtained from (18)F-FDG PET\/CT","volume":"11","author":"Kang","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jhepr.2026.101901_bib35","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1159\/000516565","article-title":"Pretreatment positron emission tomography with 18F-fluorodeoxyglucose may Be a useful new predictor of overall prognosis following lenvatinib treatment","volume":"99","author":"Kawamura","year":"2021","journal-title":"Oncology"},{"key":"10.1016\/j.jhepr.2026.101901_bib36","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000523850","article-title":"Pretreatment positron emission tomography with 18F-fluorodeoxyglucose may Be a useful new predictor of early progressive disease following atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma","volume":"100","author":"Kawamura","year":"2022","journal-title":"Oncology"},{"key":"10.1016\/j.jhepr.2026.101901_bib37","doi-asserted-by":"crossref","first-page":"4779","DOI":"10.1002\/cncr.26099","article-title":"18F-fluorodeoxyglucose uptake on positron emission tomography as a prognostic predictor in locally advanced hepatocellular carcinoma","volume":"117","author":"Kim","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.jhepr.2026.101901_bib38","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3904\/kjim.2015.30.3.308","article-title":"Use of (18)F-FDG PET to predict tumor progression and survival in patients with intermediate hepatocellular carcinoma treated by transarterial chemoembolization","volume":"30","author":"Kim","year":"2015","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jhepr.2026.101901_bib39","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/ajt.16227","article-title":"Preoperative prediction score of hepatocellular carcinoma recurrence in living donor liver transplantation: validation of SNAPP score developed at Asan Medical Center","volume":"21","author":"Kim","year":"2021","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhepr.2026.101901_bib40","first-page":"574","article-title":"Prediction of hepatocellular carcinoma recurrence after liver transplantation by F-18-FDG PET\/CT using metabolic and volumetric parameters","volume":"55","author":"Kim","year":"2014","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jhepr.2026.101901_bib41","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1007\/s10620-015-3541-z","article-title":"Extended ischemia times promote risk of HCC recurrence in liver transplant patients","volume":"60","author":"Kornberg","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhepr.2026.101901_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14430-9","article-title":"Combining (18)F-FDG positron emission tomography with Up-to-seven criteria for selecting suitable liver transplant patients with advanced hepatocellular carcinoma","volume":"7","author":"Kornberg","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhepr.2026.101901_bib43","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1111\/j.1478-3231.2011.02541.x","article-title":"Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib","volume":"31","author":"Lee","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101901_bib44","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1097\/RLU.0000000000001422","article-title":"Prognostic value of FDG uptake of portal vein tumor thrombosis in patients with locally advanced hepatocellular carcinoma","volume":"42","author":"Lee","year":"2017","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.jhepr.2026.101901_bib45","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1007\/s00259-017-3764-7","article-title":"Volumetric parameters on FDG PET can predict early intrahepatic recurrence-free survival in patients with hepatocellular carcinoma after curative surgical resection","volume":"44","author":"Lee","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jhepr.2026.101901_bib46","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2967\/jnumed.115.167338","article-title":"Prognostic significance of (1)(8)F-FDG uptake in hepatocellular carcinoma treated with transarterial chemoembolization or concurrent chemoradiotherapy: a multicenter retrospective cohort study","volume":"57","author":"Lee","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jhepr.2026.101901_bib47","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s12149-015-0956-8","article-title":"The predictive value of metabolic tumor volume on FDG PET\/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis","volume":"29","author":"Lee","year":"2015","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.jhepr.2026.101901_bib48","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3350\/cmh.2014.20.2.192","article-title":"Impact of immunosuppressant therapy on early recurrence of hepatocellular carcinoma after liver transplantation","volume":"20","author":"Lee","year":"2014","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101901_bib49","doi-asserted-by":"crossref","first-page":"411","DOI":"10.5500\/wjt.v6.i2.411","volume":"6","author":"Lee","year":"2016","journal-title":"World J Transpl"},{"key":"10.1016\/j.jhepr.2026.101901_bib50","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1159\/000507887","article-title":"The real impact of bridging or downstaging on survival outcomes after liver transplantation for hepatocellular carcinoma","volume":"9","author":"Lee","year":"2020","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhepr.2026.101901_bib51","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.hpb.2018.10.007","article-title":"18F-FDG PET\/CT predicts microvascular invasion and early recurrence after liver resection for hepatocellular carcinoma: a prospective observational study","volume":"21","author":"Lim","year":"2019","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.jhepr.2026.101901_bib52","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2967\/jnumed.116.182022","article-title":"(18)F-FDG PET\/CT can predict survival of advanced hepatocellular carcinoma patients: a multicenter retrospective cohort study","volume":"58","author":"Na","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jhepr.2026.101901_bib53","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/MEG.0b013e3283118263","article-title":"Fluorine-18-fluorodeoxyglucose-PET\/computed tomography has a role in predicting the outcome of hepatocellular carcinoma","volume":"21","author":"Pan","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101901_bib54","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1007\/s00268-017-4275-1","article-title":"The clinical implications of liver resection margin size in patients with hepatocellular carcinoma in terms of positron emission tomography positivity","volume":"42","author":"Park","year":"2018","journal-title":"World J Surg"},{"key":"10.1016\/j.jhepr.2026.101901_bib55","article-title":"11C-acetate and 18F-fluorodeoxyglucose positron emission tomography\/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemoembolization","volume":"97","author":"Park","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhepr.2026.101901_bib56","first-page":"1047","article-title":"Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma","volume":"33","author":"Paudyal","year":"2008","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jhepr.2026.101901_bib57","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/liv.13297","article-title":"Risk stratification for locally advanced hepatocellular carcinoma using pretreatment alpha-foetoprotein and (18) F-fluoro-2-deoxyglucose positron emission tomography","volume":"37","author":"Rhee","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhepr.2026.101901_bib58","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1158\/1078-0432.CCR-06-1357","article-title":"Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma","volume":"13","author":"Seo","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhepr.2026.101901_bib59","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00280-010-1454-2","article-title":"Prognostic implication of (18)F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study","volume":"68","author":"Shin","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.jhepr.2026.101901_bib60","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.crad.2014.09.020","article-title":"Value of 18F-FDG PET\/CT in detecting viable tumour and predicting prognosis of hepatocellular carcinoma after TACE","volume":"70","author":"Song","year":"2015","journal-title":"Clin Radiol"},{"key":"10.1016\/j.jhepr.2026.101901_bib61","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00259-013-2366-2","article-title":"18F-fluorodeoxyglucose PET\/CT predicts tumour progression after transarterial chemoembolization in hepatocellular carcinoma","volume":"40","author":"Song","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jhepr.2026.101901_bib62","first-page":"3215","article-title":"Predictive value of (1)(8)F-fluorodeoxyglucose PET\/CT for transarterial chemolipiodolization of hepatocellular carcinoma","volume":"18","author":"Song","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhepr.2026.101901_bib63","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1097\/MNM.0000000000000842","article-title":"Prognostic value of pretreatment PET\/CT lean body mass-corrected parameters in patients with hepatocellular carcinoma","volume":"39","author":"Sun","year":"2018","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.jhepr.2026.101901_bib64","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1007\/s00259-017-3871-5","article-title":"(18)F-fluorodeoxyglucose uptake of hepatocellular carcinoma as a prognostic predictor in patients with sorafenib treatment","volume":"45","author":"Sung","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jhepr.2026.101901_bib65","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s00259-016-3583-2","article-title":"Refining prognosis in patients with hepatocellular carcinoma through incorporation of metabolic imaging biomarkers","volume":"44","author":"Takeuchi","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jhepr.2026.101901_bib66","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/JHC.S401647","article-title":"Metabolic tumor volume measured by (18)F-FDG PET\/CT is associated with the survival of unresectable hepatocellular carcinoma treated with PD-1\/PD-L1 inhibitors plus molecular targeted agents","volume":"10","author":"Wang","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.jhepr.2026.101901_bib67","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.hbpd.2020.03.009","article-title":"Alpha-fetoprotein and (18)F-FDG standard uptake value predict tumor recurrence after liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis: preliminary experience","volume":"19","author":"Yang","year":"2020","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.jhepr.2026.101901_bib68","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1499-3872(17)60011-0","article-title":"Role of [(18)F] fludeoxyglucose positron emission tomography in the selection of liver transplantation candidates in patients with hepatocellular carcinoma","volume":"16","author":"Ye","year":"2017","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"10.1016\/j.jhepr.2026.101901_bib69","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1007\/s00268-021-06235-9","article-title":"Identifying patients who may benefit from liver resection compared to living donor liver transplantation for hepatocellular carcinoma using (18)F-FDG PET","volume":"45","author":"Yoh","year":"2021","journal-title":"World J Surg"},{"key":"10.1016\/j.jhepr.2026.101901_bib70","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhepr.2026.101901_bib71","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S2468-1253(25)00011-1","article-title":"[(18)F]fluorodeoxyglucose and [(18)F]fluorocholine PET-CT for staging optimisation and treatment modification in hepatocellular carcinoma (PET-HCC01): a prospective multicentre study","volume":"10","author":"Nault","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhepr.2026.101901_bib72","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00259-004-1602-1","article-title":"Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography","volume":"31","author":"Lee","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jhepr.2026.101901_bib73","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.2967\/jnumed.108.055087","article-title":"A prospective evaluation of 18F-FDG and 11C-acetate PET\/CT for detection of primary and metastatic hepatocellular carcinoma","volume":"49","author":"Park","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.jhepr.2026.101901_bib74","first-page":"224","article-title":"(18)F-FDG-PET for assessing biological viability and prognosis in liver transplant patients with hepatocellular carcinoma","volume":"5","author":"Kornberg","year":"2017","journal-title":"J Clin Transl Hepatol"}],"container-title":["JHEP Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926001722?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589555926001722?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:41:04Z","timestamp":1793148064000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589555926001722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2589555926001722"],"URL":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101901","relation":{},"ISSN":["2589-5559"],"issn-type":[{"value":"2589-5559","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic significance of pretreatment 18F-FDG PET\/CT in hepatocellular carcinoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"JHEP Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhepr.2026.101901","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).","name":"copyright","label":"Copyright"}],"article-number":"101901"}}